ClinicalTrials.gg
CompletedNCT04752709Updated Dec 30, 2024Results posted

Efficacy of Surface Electrical Stimulation for Urge Urinary Incontinence in Women

An interventional study of ELITONE UUI in Urge Incontinence, sponsored by Elidah, Inc.. Completed at 1 site in United States. Open to female participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-12-30.

Sponsored by Elidah, Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
21 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 135 studies in Urinary Incontinence, Urge with a site in United States — 19 open to participants now, 26 under way, none of them phase 3. Urinary Incontinence, Urge · United States.

Enrollment
58th of 119
82 · median 75
Started
2020
with 9 others
No phase
72 of 135
10 open now
Registered
96th of 135
by date

Among the 135 studies in Urinary Incontinence, Urge with a site in United States, this one is the 58th largest by enrollment of the 119 interventional ones that give a count, is one of 10 that started in 2020, is one of 72 with no phase, and was the 96th registered.

Urinary Incontinence, Urge

243 studies on the registry are indexed under Urinary Incontinence, Urge; 39 are open to participants now.

Browse Urinary Incontinence, Urge studies →

Open to participants now

19 of the 135 studies in Urinary Incontinence, Urge with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Urinary Incontinence, Urge studies recruiting now, 18 (72%) set no upper age limit and 2 (8%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 21 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 135 studies in Urinary Incontinence, Urge with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research is to evaluate the effectiveness of the ELITONE-UUI electrical muscle stimulation device on treating urge incontinence. The aim of the device is to stimulate the pelvic floor muscles and surrounding structures to improve urinary incontinence.

Read the detailed description

The purpose of this research is to evaluate the effectiveness of the ELITONE-UUI electrical muscle stimulation device on treating urge incontinence in women. The aim of the device is to stimulate the pelvic floor muscles and surrounding structures to improve urinary incontinence. This is a randomized prospective controlled study of two active groups with a stimulation frequency difference between the groups.

03

Conditions studied

  • Urge Incontinence

Keywords

  • incontinence
  • bladder
  • urge
  • urgency
  • stimulation
04

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Predominant urge urinary incontinence as determined by responses to a series of three standard questions from the King's Health Questionnaire; specifically:

    • An affirmative response to "Is it very difficult to control when you have a strong urge to urinate?",
    • An affirmative or negative response to "Do you lose urine with physical activities such as coughing, sneezing, running?",
    • And, if an affirmative response to the second question, an affirmative response to "Are more of your incontinence episodes due to a strong urge to urinate than to abdominal pressure such as sneezing?"
  • Mild-moderate incontinence symptoms as determined by self-reported typical number of accidents of 1 or more per 24 hours. Symptom severity is later verified with data from the Daily Log (See 5.4)

Exclusion criteria

Exclusion Criteria:

  • Less than 1 incontinence accident (leak) per day*
  • Severe incontinence as determined by self-reported >5 accidents per day
  • Currently pregnant, may be pregnant, attempting to become pregnant, or delivery within previous 6 weeks
  • Vaginal or pelvic surgery within previous 6 months
  • Severe Obesity as defined by >= 35
  • Change in incontinence medication type or dosing within the last 3 months.
  • History or symptoms of urinary retention, extra-urethral incontinence, overflow incontinence
  • Pelvic pain/painful bladder syndrome
  • Active urinary tract infection (UTI) or history of recurrent UTIs (more than three in a year), or recurrent vaginitis (bacterial/fungal)
  • Tissues protruding outside the vagina at rest
  • Presence of incontinence-associated dermatitis or other perineal skin disorders or lesions,
  • Complete denervation of the pelvic floor
  • Conductive inter-uterine devise (IUD/Coil) or metal implants in the abdominal or pelvic area, including the hip and lumbar spine,
  • Chronic coughing
  • Previous use of Interstim device or Botox for UI
  • Implanted cardiac device, untreated cardiac arrhythmia or suffer from other heart problems.
  • Cancer, epilepsy or cognitive dysfunction
  • Underlying neurologic/neuromuscular disorder
  • Impaired decision making, suicidal thoughts, or drug/alcohol dependence
  • Lacks capacity to consent for themselves.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    Active Group A

    Electrical muscle stimulator and surface applied electrode shaped to fit the perineal region, with stimulation group A.

    Device: ELITONE UUI

  • Active comparator
    Active Group B

    Electrical muscle stimulator and surface applied electrode shaped to fit the perineal region with stimulation group B.

    Device: ELITONE UUI

Interventions

  • DeviceELITONE UUI

    External electrical stimulation

    Also known as: ELITONE muscle stimulator

06

What researchers measure

Primary outcomes

  1. Change in Average Number of Urinary Incontinence Episodes Per Day

    The efficacy of a treatment for urinary incontinence measures how much the treatment changed urinary incontinence leakage from the beginning to the end of the 6 week period.

    Time frame: 6 weeks

  2. Safety Assessed by Number of Serious Adverse Events

    Any serious adverse events recorded during the trial.

    Time frame: 6 weeks

Secondary outcomes

  1. Efficacy Assessed by Change in Incontinence Quality of Life Questionnaire (I-QOL)

    The efficacy assessed by change in Incontinence quality of life questionnaire (I-QOL). The scale is as follows: 1 = not at all , 2 = a little, 3 = moderately, 4 = quite a bit and 5 = extremely. The lower the value the less times it happens and the better outcome. A larger results indicate a higher change in I-QOL from beginning to end of trial. The minimum score total is 22 and maximum total score is 110.

    Time frame: 6 weeks

  2. Efficacy Assessed by Reduction in Average Pads Used Per Day

    Efficacy Assessed by Reduction in Average Pads used per day over the 6 week period.

    Time frame: 6 weeks

  3. Efficacy Assessed by Reduction in Average Bathroom Visits

    The efficacy assessed by average bathroom visits during the day and night.

    Time frame: 6 weeks

07

Results

Posted Dec 30, 2024

Participant flow

Participant flow — Overall Study
MilestoneActive Group AActive Group B
Started2656
Completed1734
Not completed922

Outcome measures

PrimaryChange in Average Number of Urinary Incontinence Episodes Per Day

The efficacy of a treatment for urinary incontinence measures how much the treatment changed urinary incontinence leakage from the beginning to the end of the 6 week period.

Time frame:
6 weeks
Reported as:
Mean · percentage change
Change in Average Number of Urinary Incontinence Episodes Per Day
percentage changeActive Group AActive Group B
Change in Average Number of Urinary Incontinence Episodes Per Day69.6 ± 30.966.1 ± 28.7
Statistical analysis
  • Active Group A vs Active Group B · t-test, 2 sided · p = <0.0001
PrimarySafety Assessed by Number of Serious Adverse Events

Any serious adverse events recorded during the trial.

Time frame:
6 weeks
Reported as:
Mean · serious adverse events
Safety Assessed by Number of Serious Adverse Events
serious adverse eventsActive Group AActive Group B
Safety Assessed by Number of Serious Adverse Events0 ± 00 ± 0
SecondaryEfficacy Assessed by Change in Incontinence Quality of Life Questionnaire (I-QOL)

The efficacy assessed by change in Incontinence quality of life questionnaire (I-QOL). The scale is as follows: 1 = not at all , 2 = a little, 3 = moderately, 4 = quite a bit and 5 = extremely. The lower the value the less times it happens and the better outcome. A larger results indicate a higher change in I-QOL from beginning to end of trial. The minimum score total is 22 and maximum total score is 110.

Time frame:
6 weeks
Reported as:
Mean · change of score on a scale
Efficacy Assessed by Change in Incontinence Quality of Life Questionnaire (I-QOL)
change of score on a scaleActive Group AActive Group B
Efficacy Assessed by Change in Incontinence Quality of Life Questionnaire (I-QOL)-26.6 ± 20.2-21.8 ± 15.9
SecondaryEfficacy Assessed by Reduction in Average Pads Used Per Day

Efficacy Assessed by Reduction in Average Pads used per day over the 6 week period.

Time frame:
6 weeks
Reported as:
Mean · percentage of change
Efficacy Assessed by Reduction in Average Pads Used Per Day
percentage of changeActive Group AActive Group B
Efficacy Assessed by Reduction in Average Pads Used Per Day27.8 ± 57.436.4 ± 33.5
SecondaryEfficacy Assessed by Reduction in Average Bathroom Visits

The efficacy assessed by average bathroom visits during the day and night.

Time frame:
6 weeks
Reported as:
Mean · percentage of change
Efficacy Assessed by Reduction in Average Bathroom Visits
percentage of changeActive Group AActive Group B
Efficacy Assessed by Reduction in Average Bathroom Visits5.9 ± 29.50.5 ± 26.0

Adverse events

Collected over 6 weeks of study. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active Group A0/17 (0%)0/17 (0%)0/17 (0%)
Active Group B0/34 (0%)0/34 (0%)0/34 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Active Group AActive Group BTotal
<=18 years000
Between 18 and 65 years132336
>=65 years41115
Age, Continuous
Age, Continuous(years)Active Group AActive Group BTotal
Mean53.0 ± 13.857.8 ± 12.756.2 ± 13.1
Sex: Female, Male
Sex: Female, Male(Participants)Active Group AActive Group BTotal
Female173451
Male000
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Active Group AActive Group BTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)Active Group AActive Group BTotal
United States173451
08

Study locations

1 site
  • Elidah
    Monroe, Connecticut 06468, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in May 2021, 6 months.

Results were first posted in Dec 2024, 3 years 7 months after primary completion.

Of 77 interventional studies with no phase under Urinary Incontinence, Urge, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2021
First posted
Feb 12, 2021
StartActual
Nov 19, 2020
Primary completionActual
May 30, 2021
CompletionActual
Sep 30, 2021
Results first posted
Dec 30, 2024
Last update
Dec 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04752709
Lead sponsor
Elidah, Inc.
Responsible party
Sponsor
First posted
Feb 12, 2021
Start date
Nov 19, 2020
Primary completion
May 30, 2021
Completion
Sep 30, 2021
Results posted
Dec 30, 2024
Last update
Dec 30, 2024

Study contacts

Gloria Kolb, M.S.
study director · Elidah, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion